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Abstract
Although potent combination therapy is usually able to suppress plasma viral loads in HIV-1 patients to below the detection
limit of conventional clinical assays, a low level of viremia frequently can be detected in plasma by more sensitive assays.
Additionally, many patients experience transient episodes of viremia above the detection limit, termed viral blips, even after
being on highly suppressive therapy for many years. An obstacle to viral eradication is the persistence of a latent reservoir
for HIV-1 in resting memory CD4
+ T cells. The mechanisms underlying low viral load persistence, slow decay of the latent
reservoir, and intermittent viral blips are not fully characterized. The quantitative contributions of residual viral replication to
viral and the latent reservoir persistence remain unclear. In this paper, we probe these issues by developing a mathematical
model that considers latently infected cell activation in response to stochastic antigenic stimulation. We demonstrate that
programmed expansion and contraction of latently infected cells upon immune activation can generate both low-level
persistent viremia and intermittent viral blips. Also, a small fraction of activated T cells revert to latency, providing a
potential to replenish the latent reservoir. By this means, occasional activation of latently infected cells can explain the
variable decay characteristics of the latent reservoir observed in different clinical studies. Finally, we propose a
phenomenological model that includes a logistic term representing homeostatic proliferation of latently infected cells. The
model is simple but can robustly generate the multiphasic viral decline seen after initiation of therapy, as well as low-level
persistent viremia and intermittent HIV-1 blips. Using these models, we provide a quantitative and integrated prospective
into the long-term dynamics of HIV-1 and the latent reservoir in the setting of potent antiretroviral therapy.
Citation: Rong L, Perelson AS (2009) Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on
Potent Therapy. PLoS Comput Biol 5(10): e1000533. doi:10.1371/journal.pcbi.1000533
Editor: Rustom Antia, Emory University, United States of America
Received April 30, 2009; Accepted September 15, 2009; Published October 16, 2009
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: Portions of this work were done under the auspices of the US Department of Energy (DOE) under contract DE-AC52-06NA25396. This work was
supported by NIH grants AI28433 and RR06555. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: asp@lanl.gov
Introduction
Following initiation of highly active antiretroviral therapy
(HAART) the plasma viral load declines with a rapid first phase,
followed by a slower second phase (Figure 1, see reviews in [1–3]).
After several months of treatment, most patients attain a level of
plasma HIV-1 RNA below the detection limit (e.g., 50 copies/mL)
of current standard assays [4–6]. However, this does not imply that
viral replication has been completely suppressed by therapy. On the
contrary,eveninpatients with ‘‘undetectable’’plasmaviralloadsfor
many years, a low level of virus can be detected in plasma by
supersensitive assays [7–9]. This phase with HIV-1 RNA below 50
copies/mL has been referred to as the third phase of viral decline
after treatment [1] (Figure 1), although whether virus declines or
persists at a constant level is still unresolved [9,10]. The factors
influencing this low-level viral persistence and their relative
contributions have not been fully elucidated. It is possible that
currentHAARTregimensarenotcompletelysuppressive and HIV-
1 continues to replicate, particularly in some drug sanctuary sites
such as the brain and testes, where drugs have poor penetration (see
[11,12] and reviews in [13,14]). A second explanation is that HIV-1
establishes a state of latent infection in resting memory CD4z T
cells [15,16], and virus is released when these cells encounter their
relevant antigens and are reactivated [17]. The latent reservoir
persists in patients on HAART [18–20] and decays slowly, with the
estimated half-life up to 44 months [21,22]. It is more likely that
both factors contribute to viral persistence. The latent reservoir
releases virus that fuels ongoing viral replication, and ongoing viral
replication replenishes the latent reservoir. We still lack a
quantitative understanding of the relative contributions from
residual ongoing viral replication and latent cell activation to the
observed sustained low-level viremia.
Another line of evidence for HIV-1 persistence is the observation
of transient episodes of viremia (‘‘blips’’) above the detection limit in
patients on HAART (Figure 1) [7,23]. Because viral blips are
relatively rare events, their occurrence time, frequency, duration
and amplitude are not well known. Di Mascio et al. [24] studied
viral load time series with samples obtained approximately one
month apart from 123 patients, and found that the mean blip
frequency was 0:09+0:11=sample, and the mean blip amplitude
was 158+132 RNA copies/mL. They also suggested that a viral
blip was not an isolated event but rather an extended transient
episodeofviremia with adurationofapproximately3 weeks[25].In
another study, Nettles et al. [26] examined the dynamics of blips
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patients. They found that blips were brief with a mean duration of
less than 3 days and had a mean amplitude of 79 copies/mL.
Moreover, viral blips were not concordant on independent testing,
indicating that random biological or statistical variation around a
mean viral load less than 50 copies/mL might be responsible for the
aberrant viral load measurements [26]. The observations by these
studies may represent different phenomena, with Nettles et al. [26]
observing the effects of assay variation and Di Mascio et al. [24]
observing higher amplitude blips generated by occasional immune
activation events [27].
The management of HIV-1 infection requires a further
understanding of the mechanisms underlying low viral load
persistence, stability of the latent reservoir, and occurrence of
intermittent viral blips, as well as the relationships between them.
We approach this through mathematical modeling. Many models,
as surveyed in [28], are not capable of realistically accounting for
viral load persistence since the presence of low-level replication is
extremely sensitive to small changes of drug efficacy. Studies of the
dynamics of the latent reservoir and viral blips are also difficult
because latently infected cells are very rare [15] and blips appear
to emerge randomly [24,26]. Considering the heterogeneity of the
pool of latently infected cells, a simple model was developed to
study the decay characteristics of the latent reservoir [29]. Kim
and Perelson [30] extended the model and showed that the latent
reservoir persistence could be explained by bystander proliferation
of latently infected cells. The relationship between low-level viral
replication and the decay of the latent reservoir was examined in a
recent study by Sedaghat et al. [31]. They developed a simple
model considering the transition between latently infected and
activated T cells. The results demonstrated that viral dynamics in
patients under HAART might be consistent with low-level viral
replication but the replication did not have much impact on the
decay rate of the latent reservoir, which confirms their earlier
modeling predictions [32]. Mathematical models have also been
proposed to test possible mechanisms for the generation of viral
blips. Jones and Perelson showed that activation of either target T
cells [33] or latently infected cells [27] could result in a burst of
virus production. Asymmetric division of activated latently
infected cells may explain the variable decay kinetics of the latent
reservoir and intermittent viral blips [34].
In this paper, we further study latently infected cell activation
in response to antigenic stimulation by extending the models in
[27,30,33]. We examine the hypothesis that stochastic activation
of latently infected cells can generate intermittent viral blips and
maintain low-level plasma viremia, without seriously depleting
the latent reservoir in patients under HAART. The model
focuses on the response of latently infected cells when they
encounter their relevant antigens. We show that programmed
expansion and contraction of latently infected cells can generate
intermittent viral blips with realistic amplitude and duration.
During the latent T cell response, part of the resultant activated
T cell population reverts back to a resting state, providing a
mechanism to replenish the latent reservoir. An interesting result
of our model is that different potentials of activated T cells to
proliferate during the response or different duration or frequency
of antigenic stimulation can explain the differences between the
divergent estimates of the half-life of the latent reservoir decay in
HAART-treated patients [21–23,35–38]. Using this model, we
study the influence of ongoing viral replication on both the decay
of the latent reservoir and persistence of low-level viremia. We
perform sensitivity tests on a number of model parameters.
Finally, we develop a phenomenological model that postulates
density-dependent homeostatic proliferation of resting memory
CD4z T cells. A recent experimental study supports the idea
that homeostatic proliferation of latently infected cells may
ensure the latent reservoir persistence without any demonstrable
evidence for viral production [39]. The model can robustly
describe the multiphasic viral decline following initiation of
potent antiretroviral treatment. The different self-renewal
potentials of latently infected cells are also able to reconcile the
variable decay kinetics of the latent reservoir. Our models
provide a new perspective into the possible mechanisms for viral
and the latent reservoir persistence and emergence of intermit-
tent viral blips.
Figure 1. Multiphasic viral decline after potent treatment. After
initiation of HAART, the plasma viral load undergoes a multiphasic
decay and declines to below the detection limit (e.g., 50 RNA copies/
mL) of standard assays after several months. A low level of viremia
below 50 copies/mL may persist in patients for many years despite
apparently effective antiretroviral treatment. Intermittent viral blips
with transient HIV-1 RNA above the limit of detection are usually
observed in well-suppressed patients.
doi:10.1371/journal.pcbi.1000533.g001
Author Summary
Current combination therapy can suppress viral loads in
HIV-1-infected individuals to below the detection limit of
standard commercial assays. However, it cannot eradicate
the virus from patients. HIV-1 can generally be identified in
resting memory CD4
+ T cells and persists in patients on
potent treatment for a long time. These latently infected
cells decay slowly, but can produce new virions when
activated by relevant antigens. Many patients experience
transient episodes of viremia, or blips, even though they
have ‘‘undetectable’’ plasma viral loads for many years.
Here, we develop a new mathematical model describing
latently infected cell activation upon random antigenic
stimulation. Using the model, we show that programmed
expansion and contraction of latently infected cells upon
activation can generate both low viral load persistence and
viral blips. Occasional replenishment of the latent reservoir
may explain the different decay kinetics of the reservoir
observed in clinical practice. We also show that a model
with homeostatic proliferation of latently infected cells can
explain persistence of low-level virus, stability of the latent
reservoir, and emergence of viral blips. These results
provide novel insights into the long-term virus dynamics
and could have implications for the treatment of HIV-1
infection.
Latently Infected Cell Activation
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A basic model of latent cell activation
A basic model of latent cell activation was initially developed to
examine the cell populations contributing to the second-phase
viral decline after administration of both reverse transcriptase (RT)
and protease inhibitors [4]. Using an overall drug efficacy, , the
basic model can be reduced to the simpler form [34]:
d
dt
T(t)~l{dTT{(1{ )kVT,
d
dt
L(t)~g(1{ )kVT{d0L{aLL,
d
dt
T (t)~(1{g)(1{ )kVT{dT zaLL,
d
dt
V(t)~NdT {cV,
ð1Þ
where T represents CD4z T cells that are susceptible to HIV-1
infection, T  represents productively infected cells that can
produce virus particles, L represents latently infected cells that
cannot produce virus but are ready to do so once they are
activated by their recall antigens, and V represents the total viral
load. l is the recruitment rate of susceptible T cells and dT is their
mortality rate. The constant k is the infection rate. d and d0 are
the death rate of productively and latently infected cells,
respectively. c is the clearance rate of free virus. N is the burst
size, the total number of virions produced by an infected cell
during its life span. g is the fraction of infections that lead to
latency. aL is the transition rate at which latently infected cells
become productively infected cells. is the total drug efficacy,
which is defined as ~1{(1{ RT)(1{ PI) where RT and PI
are the drug efficacy of RT and protease inhibitor, respectively.
There is only one positive steady state viral load of Eq. (1):
{
V~
Nl
c
(1{
d0
d0zaL
g){
dT
(1{ )k
: ð2Þ
It is biologically plausible if and only if is less than a ‘‘critical
efficacy’’, given by
c~1{
cdT
kNl(1{
d0
d0zaL
g)
: ð3Þ
If § c, then the only steady state is the uninfected steady state,
with
{
V~
{
T  ~
{
L~0,
{
Tw0. The steady state viral load (2) can
theoretically achieve any positive value close to zero. However, it
remains very sensitive to small changes of drug efficacy,
particularly when approaches c [28,34]. Therefore, the basic
model and its various variations [28] are not realistic to describe
the persistence of low-level viremia in patients on HAART.
Furthermore, the model cannot maintain the latent reservoir size
unless the death rate of latently infected cells (d0) and the
transition rate (aL) are both chosen to be very small [31]. If
transient episodes of viremia also come from activation of latently
infected cells as suggested in [40], then the latent reservoir will be
depleted more quickly than observed in clinical studies.
Model with programmed expansion and contraction of
latently infected cells upon activation
Both CD4z and CD8z T cell responses to infectious agents (for
example, lymphocytic choriomeningitis virus (LCMV) [41] and
Listeria monocytogenes [42])canbebrokendown into threedistinct
phases: expansion/activation, contraction/death and mainte-
nance/memory [43]. Upon initial exposure to antigen, specific T
cells undergo considerable antigen-driven expansion and differen-
tiation into effector cells, whose major function is to kill infected
cells. A contraction or death phase then ensues, in which the
majority of activated T cells die quickly by apoptosis or activation-
induced cell death. The third phase is characterized by a stable [44]
or slowly decaying pool [45] of memory cells, which are formed
during the response and are maintained for long periods of time. By
developing mathematical models considering these phases, De Boer
et al. studied the dynamics of the CD8z T cell response to LCMV
[44] and compared them with the CD4z T cell response to LCMV
[45]. Fitting models to experimental data, they obtained the T cell
doubling time during the expansion phase and the T cell half-life
during the contraction phase. These results suggest that the CD8z
T cellresponsehas fasterkinetics inalmost every aspectthan CD4z
T cells [45]. Jones and Perelson [33] developed a model that
accounts for both HIV infection and the programmed cascade of
divisions during the expansion of the CD8z T cell response to a
concurrent opportunistic infection. Using the model, they showed
that targetcell activation[33]or latent cell activation [27] caused by
opportunistic infections was able to explain the transient low-level
viremia observed in well-suppressed patients on potent treatment.
Here, we reexamine the model in [27] and develop a new one in
which latently infected cells are hypothesized to experience
programmed expansion and contraction in response to their specific
antigens, and in which a small portion of activated cells revert back
to the resting state by the process that normally generates memory
CD4z T cells(Figure 2).Weinvestigate whetherrepeated latent cell
activation through this type of programmed response can generate
intermittent viralblips with reasonable amplitude and duration, and
whether the replenishment of latently infected cells can control the
decay of the latent reservoir.
Let L0 represent the concentration of resting latently infected
CD4z T cells. These cells on encounter with their relevant
antigens may enter the class of activated cells, La. One model
describing the programmed expansion and contraction of latently
infected cells upon antigenic stimulation is as follows:
d
dt
T(t)~l{dTT{(1{ )kVT,
d
dt
L0(t)~g(1{ )kVT{d0L0{f(t)aL0z(1{f(t))rLa,
d
dt
La(t)~f(t)(aL0zpLa){(1{f(t))(azr)La{aLLa,
d
dt
T (t)~(1{g)(1{ )kVT{d(T )T zaLLa,
d
dt
V(t)~pvT {cV:
ð4Þ
When the antigen is present, resting latently infected cells, L0, are
activated into the activated class La with rate constant a. The
function f(t) determines the times at which antigen is present at
concentration sufficiently high to activate cells. Activated cells
proliferate at rate p. Once the antigen concentration falls, we
assume there is a contraction phase, in which activated cells die or
apoptose at rate a, or revert to the resting state at rate r.I n
addition, activated latently infected cells transition into produc-
tively infected cells at rate aL during the entire response.
As suggested by [28,46], we use a density-dependent death rate of
productively infected cells in order to reduce the sensitivity of the
steady state viral load to changes of drug efficacy. The biological
justification for the density-dependent cell death rate is as follows:
productively infected cell can be killed at a rate that depends on the
density of effector cells. The population size of effector cells can be
Latently Infected Cell Activation
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Thus, the death rate of productively infected cells can be assumed to
be a function of the infected cell density. We choose a simple power-
law function, d(T )~d’T v
, as used in [28,46], where v controlsthe
size of the immune effect on the death rate. Holte et al. [46] obtained
estimatesofv by fitting the density-dependent decay model to patient
data. Because the model includes a density-dependent infected cell
death rate, we have to decouple the viral production rate from the cell
death rate. We assume virus is produced at a constant rate, pv,p e r
productively infected cell, T . For simplicity, we assume pv~N.A
modification of this model will be given later to study viral persistence
without the assumption of density-dependent infected cell death.
We employ a basic ‘‘on-off’’ model, which has previously been
used to describe the CD4z and CD8z T cell responses to viral
infection [44,45], to approximate the antigenic stimulation of latently
infected cells instead of explicitly modeling the interaction between
naive T cells and their specific antigens as was done in [27,33]. The
activation function, f(t), is antigen-dependent and takes on only two
values: 0 if there is no activation, and 1 if there is full activation. If Ton
is the time at which the stimulation switches ‘‘on’’ and Toff isthe time
at which the stimulation is ‘‘off’’, then f(t) assumes the following
expression:
f(t)~
0i f tvTon,
1i f TonƒtvToff,
0i f t§Toff:
8
> <
> :
ð5Þ
We denote by Dt~Toff{Ton the duration that each activation lasts.
Although CD4z and CD8z T cells both commit to clonal
expansionafterantigenicstimulation,CD8z T cellstypicallyhavea
higher proliferative potential both in vitro and in vivo compared with
CD4z T cells [41,47]. It has been estimated that CD8z T cells
divide about 15{20 times during an acute infection with LCMV,
while CD4z T cells divide approximately 9 times [41]. Choosing
the proliferation rate of CD4z T cells as in [45], p~1:4 day{1,
CD4z T cells can divide 8 to 12 times if the expansion phase lasts
4{6 days. If p~0:8 day{1,t h e nCD4z T cells only divide 5 to 7
times over the same period. With various proliferation rates, we will
show that the number of times that activated latently infected cells
divide upon stimulation is an influential factor that not only controls
the decay of the latent reservoirbutthat alsoaffects the amplitude of
viral blips. Because only a small fraction of latently infected cells are
specific for any given antigen, we choose a to be 0:03 day{1.W e
will perform sensitivity tests on a few parameters including a.T h e
death rate of activated cells during the contraction phase, a, is not
well-known. In [45], about 0:2 day{1 was estimated for this
parameter. Because the cells activated from latently infected cells
are usually not observed, here we choose a larger death rate,
a~0:8 day{1, such that activated latently infected cells will decline
to low levels after a relatively short period. We will discuss the effect
of a smaller a later. We also assume that a small fraction of activated
cells revert back to the resting state, with rate r~0:01 day{1 [27],
whereasanotherportion ofthem transitionintothe productive stage
with rate aL~0:1 day{1. We will test our model predictions with
different values of r and aL.
We choose the overall drug efficacy ~0:85 as the baseline
value so that viral load can be suppressed to below the detection
limit after several months of treatment. In fact, as we will show
below, specific values of the drug efficacy do not strongly impact
viral and the latent reservoir persistence once it exceeds a
threshold called the critical efficacy. The dynamics of viral load,
Figure 2. Schematic representation of the model with latently infected cell activation (Eq. (4)). Following encounter with cell-specific
antigens, latently infected cells are activated and undergo programmed clonal expansion and contraction. A number of activated latently infected
cells transition to the productive class and produce virions, whereas another small fraction of activated cells revert back to the latent state, providing
a mechanism to replenish the latent reservoir.
doi:10.1371/journal.pcbi.1000533.g002
Latently Infected Cell Activation
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different drug efficacies. Similar arguments can be applied to the
choice of the value of g, the fraction of infections resulting in
latency. As long as it represents a small fraction of infections, the
value of g has only a minor effect. Here we choose g~0:001 [27]
as an example. The form of the activation function f(t) will be
further discussed below. The viral burst size, N, can affect the
amplitude of blips generated from activation of latently infected
cells. Here we use N~2000 [48], although recently higher values
of N have been estimated for SIV [49]. It is not known if these
higher burst sizes apply to HIV. However, if higher values of N
are used, then other parameters in Table 1 need to be adjusted,
such as the viral clearance rate, which recent work suggests may be
higher in tissue than has been estimated in blood (De Boer R.,
Ribeiro R. and Perelson AS, unpublished results). The other
parameter values are chosen based on previously published reports
and are summarized in Table 1.
Since we are interested in the dynamics of the third-phase
viral decline during treatment, we choose the initial viral load
to be V(0)~50 RNA copies=mL. With an assumption of quasi-
steady state between virions and productively infected cells, we
obtain the initial condition for productively infected cells,
T (0)~0:3 cells=mL. We set T(0)~600 cells=mL as the initial
condition for target T cells [30]. The total number of latently
infected cells with replication-competent viral genomes is assumed
to be 5|105 cells [15], 98% of which are in the lymphoid tissue
and the rest are in the blood. Assuming the blood volume is 5 L,
the concentration of latently infected cells with replication-
competent provirus is 2 cells/mL, i.e., L0(0)~2 cells=mL.W e
assume there are no activated latently infected cells initially, i.e.,
La(0)~0.
Model with a biphasic contraction phase
Homann et al. [41] suggested a multiphasic contraction phase in
the CD4z T cell response to acute LCMV infection. De Boer et al.
[45] developed a mathematical model that fits the Homann data
using two distinct phases of activated cell death after the peak of the
response. Here, we modify model (4) by adopting a biphasic
contraction phase in the latently infected CD4z T cell response.
More motivations will be addressed in the Results section after we
present theresults ofmodel(4).Inthemodifiedmodel,theT andL0
equations remain the same, while the other equations change to
Table 1. Variables, parameters and values used in models and simulations.
Variable/Parameter Value Description Reference
T(t) - Target T cells -
L(t) - Latently infected cells -
L0(t) - Resting latently infected cells -
La(t) - Activated latently infected cells -
T (t) - Productively infected cells -
V(t) - Viral load -
l 104 ml{1 day{1 Recruitment rate of susceptible cells [28]
dT 0:01 day{1 Death rate of susceptible cells [90]
k 2:4|10{8 ml day{1 Infection rate [50]
0.85 Overall drug efficacy see text
g 0:001 Fraction resulting in latency [27]
d0 0:001 day{1 Death rate of latently infected cells [28]
aL 0:1 day{1 Rate of transition from latently to see text
productively infected cells
d 1 day{1 Death rate of productively infected cells [91]
N 2000 Burst size [48]
c 23 day{1 Clearance rate of free virus [92]
d’ 0:7863 day{1(ml=cell)
v Density-dependent mortality [28]
v 0:44 Power in density-dependent mortality function [46]
pv 2000 day{1 Viral production rate [48]
p varied Proliferation rate of activated cells see text
a 0:03 day{1 Activation rate of latent cells see text
a 0:8 day{1 Death rate of activated cells see text
r 0:01 day{1 Reversion rate to latency [27]
da 0:02 day{1 Base death rate of activated cells [45]
r varied Maximum proliferation rate of latent cells see text
Lmax varied Carrying capacity density of latent cells see text
f(t) see text Expansion function -
g(t) see text Rapid contraction function -
doi:10.1371/journal.pcbi.1000533.t001
Latently Infected Cell Activation
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dt
La(t)~f(t)(aL0zpLa){(1 {f(t))(dazr)La{g(t)aLa{aLLa,
d
dt
T (t)~(1{g)(1{ )kVT{dT zaLLa,
d
dt
V(t)~NdT {cV,
ð6Þ
where f(t) is the expansion function defined by Eq. (5). Following
the expansion phase, there is a two-phase contraction: a rapid
contraction phase of length Dtc, where activated cells die rapidly by
apoptosis or activation-induced cell death, at a rate a, and a slower
phase where activated cells die at their base mortality rate da. For
simplicity, we assume the rapid contraction phase has the same
length as the expansion phase (i.e., Dt~Dtc). g(t) represents the
contraction function. During the rapid contraction phase, g(t)~1,
otherwise, g(t)~0.
A phenomenological model with homeostasis of latently
infected cells
A recent experimental study by Chomont et al. [39] shows that
the HIV-1 latent reservoir size may be maintained by homeostatic
proliferation of latently infected cells. Thus, we incorporate a
logistic term representing homeostatic proliferation of latently
infected cells into the basic model (1). The L equation becomes
d
dt
L(t)~g(1{ )kVTzrL(1{
L
Lmax
){d0L{aLL: ð7Þ
The other equations for T, T  and V are the same as those in
model (1). In Eq. (7), r represents the maximum proliferation rate
and Lmax represents a threshold latent cell density, beyond which
proliferation shuts off. Whether there is such a strict maximum is
unclear and thus other forms of density-dependent proliferation
could also be explored, such as rL=(KzL), where K is a constant.
We choose a small base value for the transition rate,
aL~0:01 day{1 [27], because only a small fraction of latently
infected cells are specific for any given antigen. We will increase
the value of aL when we study latently infected cells encountering
their specific antigens, which is used to model emergence of viral
blips during treatment.
In order to maintain the latent cell pool during potent drug
therapy, we choose the proliferation rate r to be greater than
d0zaL, i.e., 0:011 day{1. In fact, it can be proved that in the case
of 100% drug effectiveness, the infected steady state exists and is
locally asymptotically stable if and only if rwd0zaL.
The carrying capacity (i.e., the maximum sustainable popula-
tion) of latently infected cells during therapy is unknown.
Assuming 1012 total body lymphocytes, Chun et al. [15] reported
a total body load of resting CD4z T cells with integrated HIV-1
DNA of *107 cells during the asymptomatic phase of infection.
Here we allow the total body carrying capacity of latently infected
cells to vary from *106 cells to *107 cells but then convert these
numbers to a cell density in blood so as to be in the same units as
the target cells, T. For example, if there are maximally 8|106
latently infected cells per patient under HAART, then the
maximum density of latently infected cells in blood is
Lmax~8|106|2%=5000~32 cells=mL since *2% of CD4z
T cells are in blood and the typical 70 kg individual has about 5L
of blood. We will discuss the effects of different values of r and
Lmax on the final model predictions.
T h es i m u l a t i o nw i t ha ni n i t i a lTc e l lc o u n tT(0)~106 cells=mL
[50]andanarbitraryinitialviralloadvalueV(0)~10{3 virions=mL
yields a set of steady state values in the absence of drug treatment:
{ T~479 cells=mL,
{
L~123 cells=mL,
{
T  ~5:2|103 cells=mL and {
V~4:5|105 virions=mL. These values are set as the initial
conditions when performing simulations of the model during
HAART.
Results
Intermittent viral blips and decay of the latent reservoir
Numerical simulations of model (4) show that programmed
expansion and contraction of latently infected cells upon
occasional antigenic stimulation can robustly generate intermittent
viral blips with reasonable amplitude and duration, without
seriously depleting the latent reservoir (Figure 3). We assume that
latently infected cells encounter their specific antigens randomly.
As an example, we assume the interval between two adjacent
activations, DT, obeys a normal distribution with a mean of 50
days and a standard deviation of 10 days. If we use a Poisson
process to model the encounter between latently infected cells and
antigen, then we get a similar pattern of viral blips and the latent
reservoir decay when the average waiting time between two
encounters is assumed to be *50 days. The duration of activated
T cell proliferation during the latent cell response remains
unknown. In fact, the mechanisms that control the rate and
extent of T cell differentiation are complicated [47]. It may involve
the amount of antigen and other types of cytokines that are present
in vivo, the duration of antigen exposure, as well as whether T cell
proliferation continues in the absence of further antigenic
stimulation [51–54]. In our simulation, we assume the duration
of activated T cell proliferation, Dt, obeys a uniform distribution
over the interval of 4 to 6 days such that CD4z T cells divide
approximately 5 to 12 times with appropriate proliferation rates
(see below) [41]. A transient episode of viremia is observed every
time an activation occurs. Thus, the timing and frequency of viral
blips are determined by when and how often latently infected cells
encounter their recall antigens. The duration of transient viremia
is determined by how long the antigen is present (Figure 3).
Another important characteristic of viral blips, the amplitude,
ranges from 50 RNA copies/mL to roughly 500 copies/mL in our
simulations. This is consistent with observations in clinical trials
[24,26,55].
An interesting result is that the amplitude of viral blips is
inversely correlated with the decay of the latent reservoir. Based
on model (4), viral blips originate from activation of latently
infected cells into the productive class. It was initially thought that
this activation would deplete the latent reservoir quickly in
HAART-treated patients because de novo infection of susceptible T
cells is maximally inhibited by potent antiretroviral drugs and
productively infected cells have a fast turnover rate. However, if
the activation induces a substantial proliferation of activated
latently infected cells, it can simultaneously reseed the latent
reservoir as a small fraction of activated cells revert to the resting
state in the formation of memory T cells. To what extent the
activation replenishes the latent cell pool depends heavily on the
proliferative potential of activated cells, i.e., how many daughter
cells are derived from the activation of latently infected cells. In
Figure 3A, the proliferation rate of activated cells is chosen to be
p~1:4 day{1, which implies that cell divisions occur 8{12 times
over an interval of 4 to 6 days. In this case, the activation induces a
high level of activated T cells. As a consequence, a large number of
productively infected cells are generated. Thus, the amplitude of
viral blips remains relatively high, and the latent reservoir is largely
replenished since more activated latently infected cells revert back
to the resting state. In our simulation, we did not observe a
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the simulation over 3 years, but only plotted the first 300 days in
Figure 3A), suggesting that the viral reservoir can be extremely
stable even with effective treatment for years. This may explain the
remarkable stability of the latent reservoir in some patients on
HAART [21]. In Figure 3B, we show an example with a slightly
smaller proliferation rate, p~1:35 day{1. In this situation,
although occasional activation can replenish the latent reservoir,
the size of the latent cell pool diminishes gradually. However, the
decay is very slow, with a half-life of approximately 44 months,
which is consistent with some estimates [21,22]. In Figure 3C,w e
choose the proliferation rate to be p~0:8 day{1, so that activated
T cells divide 5{7 times over an interval of 4 to 6 days. In this
case, a lower level of activated cells are produced, resulting in
lower amplitude viral blips. The latent reservoir is depleted
relatively quickly because cell activation consumes latently infected
cells and the replenishment of the reservoir from activated cells is
minor. Figure 3C shows a realization of model (4) in which the
decay half-life of the latent reservoir is about 6 months, which is in
agreement with the estimates in some clinical studies [23,38].
We ran stochastic simulations of the model 30 times, recorded
the number and amplitudes of viral blips, and calculated the half-
life of the decay of the latent reservoir based on the change in the
latent reservoir size in 300 days. The summary statistics on our
simulations is given in Table 2. As the proliferation rate of
activated cells (p) decreases, we observe that both the frequency
and the average amplitude of viral blips decrease. With a smaller
p, the latent reservoir size undergoes a larger decrease,
corresponding to a shorter half-life of the reservoir decay. Thus,
we expect an inverse relationship between the decay of the latent
reservoir and the frequency (or amplitude) of viral blips. This is
consistent with the experimental observations in Ramratnam et al.
[23].
The fraction of resting latently infected cells that are activated
by antigenic stimulation remains largely unknown. Due to the
heterogeneity of latently infected cells with respect to the antigens
they respond to, it is likely that a very small fraction of latently
infected cells are activated by a particular antigen. We tested
model predictions (Eq. (4)) with different activation rates a. The
proliferation rate of activated cells, p~1:35 day{1, is fixed. With
a decreasing from 0:03 day{1 (red solid) to 0:003 day{1 (black
dotted) in Figure 4A, fewer activated latently infected cells are
generated, which results in a more rapid decay of the latent
reservoir and lower viral loads. In fact, when a~0:003 day{1,5
Figure 3. Stochastic simulations of the model with programmed expansion and contraction (Eq. (4)). The model with programmed
expansion and contraction of latently infected cells can generate viral blips with reasonable amplitude and duration. DT*N(50,10), Dt*U(4,6).
Column A: p~1:4 day{1. Activated latently infected cells divide about 8{12 times over an interval [4,6] days. No statistically significant decay of the
latent reservoir is observed. Column B: p~1:35 day{1. The latent reservoir decays at a very slow rate. This realization shows a half-life of *44
months. Column C: p~0:8 day{1. Activated cells divide about 5{7 times over the same time interval. The latent reservoir decays more quickly than
it does in B, corresponding to a half-life of roughly 6 months. The other parameter values used are listed in Table 1. The blue horizontal line
represents the detection limit of 50 RNA copies/mL.
doi:10.1371/journal.pcbi.1000533.g003
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rebounds can be regarded as viral blips (w50 RNA copies=mL).
With a smaller a (e.g., 0:002 day{1), antigenic activation cannot
generate viral blips with the parameter values we used. We also
tested the sensitivity of generating blips to the transition rate aL
(Figure 4B). When aL decreases from 0:1 day{1 (red solid) to
0:01 day{1 (black dotted), the viral load does not change
significantly. However, a smaller transition rate leads to more
substantial replenishment of the latent reservoir. Viral load also
depends on the viral production rate pv. For example, when
Table 2. Summary of stochastic simulations of the model, Eq. (4), with programmed expansion and contraction of latently infected
cells.
Parameter value
Ave number
of blips over
[0, 300] days
Min blip
amplitude
(copies/mL)
Max blip
amplitude
(copies/mL)
Ave blip
amplitude
(copies/mL)
Change in the
latent reservoir
size over 300 days
Half-life of the
latent reservoir
decay (months)
p~1:4 day{1 5 186 [140, 362] 693 [541, 877] 394 [298, 522] 20.5% [219%, +26%] 1:4|103 [33, -]
p~1:35 day{1 5 168 [113, 308] 524 [346, 680] 334 [263, 446] 214% [232%, +5.5%] 46 [18, -]
p~0:8 day{1 3.7 [2, 5] 61 [50, 94] 93 [71, 111] 74 [63, 98] 265% [267%, 262%] 6.6 [6.3, 7.3]
Abbreviations: ave (average), min (minimum), max (maximum). Values above brackets are the average values over 30 simulation runs. Values in brackets are the ranges.
There are 5 antigenic activations within 300 days. When p~1:4 or 1:35 day{1, viral blip (w50 RNA copies=mL) emerges each time activation occurs. When
p~0:8 day{1, not every activation generates a viral blip. In some simulations with p~1:4 or 1:35 day{1, the latent reservoir size is predicted to increase and hence has
no half-life.
doi:10.1371/journal.pcbi.1000533.t002
Figure 4. Sensitivity tests on the activation rate a and the transition rate aL in Eq. (4). The proliferation rate of activated cells,
p~1:35 day{1, is fixed. Column A: the transition rate aL~0:1 day{1 is fixed and the activation rate a varies: a~0:03 day{1 (red solid), a~0:01 day{1
(blue dashed) and a~0:003 day{1 (black dotted). pv~2000 day{1 is fixed. Column B: the activation rate a~0:03 day{1 is fixed and the transition
rate varies: aL~0:1 day{1 (red solid), aL~0:05 day{1 (blue dashed) and aL~0:01 day{1 (black dotted). pv~2000 day{1 is fixed. Column C:
a~0:003 day{1 and aL~0:1 day{1 are fixed. The viral production rate varies: pv~2500 day{1 (red solid) and pv~2000 day{1 (black dotted). The
other parameter values used are the same as those in Figure 3. The blue horizontal line represents the detection limit of 50 RNA copies/mL.
doi:10.1371/journal.pcbi.1000533.g004
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pv~2000 day{1 (black dotted in Figure 4C). If we increase the
viral production rate to pv~2500 day{1 (red solid), then all the 3
rebounds are greater than 50 RNA copies/mL and thus generate
observable viral blips.
In addition to changing the proliferation rate (p) during
expansion, it would also be interesting to study the effects of
varying the duration (Dt) and frequency (determined by DT)o f
antigenic stimulation. As an example, we showed in Figures 5A
and 5B the latent reservoir decay and viral blips with different
distributions of Dt. Specifically, we assumed Dt*U(8,11) in
Figure 5A and Dt*U(8,10) in Figure 5B. We fixed p~0:8 day{1
and DT*N(50,10) as used in Figure 3C. No statistically
significant decay of the latent reservoir is observed in Figure 5A,
while the latent resevoir decays at a very slow rate (with a half-life
of approximately 44 months) in Figure 5B. This is not surprising
since shorter duration of activation results in generation of less
activated latently infected cells, and thus less replenishment of the
latent reservoir. In Figure 5C, we assumed Dt*U(4,6) as in
Figure 3C, but increased the frequency of activation by assuming
DT*N(30,10). In this realization, there are 8 activations in 300
days, more than the 5 activations in Figure 3C. We observe that
the latent reservoir decays more quickly than in Figure 3C. In fact,
for a large proliferation rate of activated cells (e.g., p~1:35 day{1
in Figure 3B), increasing the frequency of activation will replenish
the latent reservoir more frequently and thus decrease the decay
rate of the latent reservoir, whereas for a small proliferation rate
(e.g., p~0:8 day{1) and short duration of activation (e.g.,
Dt*U(4,6)), increasing the frequency of activation will accelerate
the latent reservoir decay (see Figures 3C and 5C).
In summary, occasional activation of latently infected cells upon
stochastic antigen encounter is able to produce a large quantity of
activated T cells temporarily, and thereby generate intermittent
viral blips. The blip amplitude/frequency is inversely correlated
with the decay of the latent reservoir. Using different potentials of
activated T cells to divide during the initial clonal expansion phase
or different duration or frequency of antigenic stimulation enables
us to generate the different decay characteristics of the latent
reservoir observed in different clinical studies [21–23,35–38].
Low-level viral persistence
We have assumed a density-dependent mortality rate for
productively infected cells in them o d e lg i v e nb yE q .( 4 )i no r d e r
to maintain a low steady state viral load when antigen is absent.
The reason that viral loads decrease very quickly in the absence
of activation in this model is that activated cells decline quickly to
Figure 5. Numerical simulations of Eq. (4) with different duration and frequency of activation. We fixed the proliferation rate of activated
cells to be p~0:8 day{1. Column A: DT*N(50,10), Dt*U(8,11). No statistically significant decay of the latent reservoir is observed. Column B:
DT*N(50,10), Dt*U(8,10). The latent reservoir decays at a very slow rate. Column C: DT*N(30,10), Dt*U(4,6). In this realization, there are 8
activations in 300 days. The latent reservoir decays more quickly than in Figure 3C. The other parameter values used are the same as those in Figure 3.
The blue horizontal line represents the detection limit of 50 RNA copies/mL.
doi:10.1371/journal.pcbi.1000533.g005
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enough cells entering the productive stage. Even when we choose
a smaller death rate of activated cells, for example, a~0:2 day{1
[45], activated cells still quickly decline to a very low level. If
activated cells can be maintained at a low level rather than
decreasing to zero quickly during the contraction phase, then low
steady state viral load persistence is possible without assuming
density-dependentinfected cell death. Astudy by Chun etal. [56]
revealed that a high level of HIV-1 proviral DNA persists in the
activated CD4z T cell compartment in infected individuals on
effective antiretroviral therapy with no detectable viremia in
plasma for extended periods of time. Although some of the
proviruses might be defective, spontaneous release of virus was
detected without any activating stimuli during overnight culture
[56]. This observation argues for the persistence of infectious
virus in activated CD4z T cells in patients under effective
treatment. Here we modify model (4) (i.e., remove the
assumption of density-dependent infected cell death and adopt
a biphasic contraction phase, see Eq. (6) in Methods) and
examine whether viral and the latent reservoir persistence, as
well as intermittent viral blips, can be generated solely by
occasional activation of latently infected cells upon encounter
with relevant antigen.
With da~0:02 day{1 [45], DT*N(50,10), Dt*U(4,6),w e
perform numerical simulations of the model with a biphasic
contraction phase. As before, we choose different proliferation
rates, i.e., (A) p~1:4 day{1,( B) p~1:35 day{1,( C)
p~0:8 day{1, to characterize different potentials of activated
cells to proliferate during the phase of expansion. Similar to
Figure 3, the simulation results shown in Figure 6 exhibit three
distinct decay profiles of the latent reservoir: (A) there is almost no
decay; (B) the latent reservoir decays at a very slow rate; (C) the
reservoir decays at a faster rate. The decay of the latent reservoir is
inversely correlated with the amplitude or frequency of viral blips.
The viral load does not decline to an unreasonably low level in the
absence of antigenic stimulation. This low-level viremia is
primarily maintained by a small number of activated cells that
transition into the productive class during the second slower
contraction phase. However, the absence of antigenic stimulation
over a long time (more than 4 months in our simulation, figure not
shown) will deplete activated cells, and the viral load will decrease
to an extremely low level (below 5|10{5virions=mL, a level that
can be interpreted as viral extinction [28]). Therefore, in order to
obtain a low level of viremia solely maintained by latently infected
cell activation, there cannot exist a very long period in which no
antigenic stimulation occurs.
Figure 6. Simulations of the model with a biphasic contraction phase (Eq. (6)). The model is able to generate viral blips as well as low-level
persistent viremia. The low-level viral load is maintained by a low level of activated latently infected cells during the second slower contraction phase
in the latent cell response. In the first row, f(t) is the expansion function (red) and g(t) is the rapid contraction function (blue). Different proliferation
rates, i.e., p~1:4 day{1 (Column A), p~1:35 day{1 (Column B), and p~0:8 day{1 (Column C), result in differential decay characteristics of the latent
reservoir as in Figure 3. The other parameter values used are listed in Table 1. The blue horizontal line represents the detection limit of 50 RNA copies/
mL.
doi:10.1371/journal.pcbi.1000533.g006
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The decay of the latent reservoir, the amplitude of viral blips,
and the viral load below the limit of detection are not largely
influenced by the effectiveness of the treatment as long as the
overall drug efficacy is beyond a threshold value, c, the critical
drug efficacy. For this model we could not obtain a closed-form
solution for c but it is numerically similar to that defined in (3). In
Figures 7A and 7B, we explore the effects of HAART potency on
the latent reservoir and low-level viremia by using different drug
efficacies: ~0:8 (red dashed line) and ~1 (blue solid line).
Although 100% effectiveness may not be clinically feasible, we use
an extreme case to illustrate the effect of latent cell activation. We
observe that for the lower drug efficacy, the latent reservoir and
the viral load are both at slightly higher levels. However, the
difference is minuscule. This shows that both the stability of the
latent reservoir and low-level persistent viral loads are principally
due to latently infected cell activation rather than ongoing active
viral replication, provided that the drug efficacy is above a certain
threshold value.
We further compare the relative contributions of ongoing viral
replication and latent cell activation to the latent reservoir and
viral persistence. In Figure 7C, we plot the ratio of g(1{ )kVT to
{f(t)aL0z(1{f(t))rLa, which represent the contributions to
the latent cell pool coming from ongoing viral replication and the
net effect of latent cell activation and return to latency,
respectively. We find that the ratio is very small, indicating that
the contribution of ongoing viral replication to the latent reservoir
size is very small. In Figure 7D, we plot the ratio of
(1{g)(1{ )kVT to aLLa, which represent the contributions to
the viral load by de novo viral infection and the transition from
activated latently infected cells into productively infected cells,
respectively. The ratio is less than 1 except a few ‘‘blips’’ where
latently infected cell activations occur. Thus, in the absence of
activation, de novo viral infection is a minor factor contributing to
the viral load, whereas viral blips are mainly due to de novo viral
infection. However, we notice that the virus causing de novo viral
infection is mainly released from latent cell activation (Figure 7C).
Therefore, viral persistence and the stability of the latent reservoir
arise primarily from occasional activation of latently infected cells
upon antigen encounter. Residual active viral replication during
HAART is only a minor factor.
We have also performed sensitivity tests on several parameters
when studying the relative contributions. The ratio of g(1{ )kVT
to {f(t)aL0z(1{f(t))rLa increases when we increase the
activation rate of latently infected cells, a, or the fraction of
infections that result in latency, g, or decrease the reversion rate to
latency, r. In Figure 8, we examined the effects of different
parameter values of a, g and r on the ratio of relative
contributions. As the activation rate a increases, more latently
infected cells are activated, leading to more substantial replenish-
ment of the latent reservoir and higher amplitudes of viral
blips. However, even when a has a 10-fold increase (notice
that in this case the transient viral load can reach above
103 RNA copies=mL, which is normally not regarded as a viral
blip), we observe that the ratio of the relative contributions
remains almost the same (Figure 8A). When the fraction of
Figure 7. Relative contributions of ongoing viral replication and latent cell activation. A and B: the effects of ongoing viral replication
(influenced by the overall drug efficacy) on the latent reservoir and viral load in the model given by Eq. (6). Different drug efficacies are used: ~0:8
(red dashed line) and ~1 (blue solid line). Ongoing viral replication is only a minor contributor to the stability of the latent reservoir and low-level
persistent viremia, as indicated by the minor effect of changing drug efficacy from ~0:8 to ~1. C and D: relative contributions of ongoing viral
replication ( ~0:8 was fixed) and latent cell activation to the latent reservoir and viral persistence. C: the ratio of g(1{ )kVT to
{f(t)aL0z(1{f(t))rLa, and D: the ratio of (1{g)(1{ )kVT to aLLa. We chose p~1:4 day{1. The other parameter values used are listed in Table 1.
doi:10.1371/journal.pcbi.1000533.g007
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latency (r) decreases, we observe similar effects on the viral load
and the ratio of contributions (Figures 8B and 8C). Viral load does
not change much. The ratio is far less than 1 (except when viral
blips occur), supporting the conclusion that the latent reservoir
persistence is mainly maintained by latently infected cell activation
rather than ongoing viral replication. Notice that with a very large
a or g or a very small r we do not generate viral blips with realistic
amplitude (Figure 8A) or a slow decay of the latent reservoir
(Figures 8B and 8C).
Homeostatic proliferation of latently infected cells:
another possible mechanism for the latent reservoir
persistence
As shown in previous sections, occasional activation of latently
infected cells upon antigen encounter can transiently produce a
large number of activated cells, a small part of which can revert to
the latent state and hence replenish the latent reservoir. In fact,
several other sources might also reseed the latent cell pool and
contribute to a stable latent reservoir: (1) homeostatic proliferation
of CD4z memory T cells regulated through combined effects of
interleukin 7 (IL-7) and T cell receptor (TCR) signaling [57]; (2)
‘‘bystander’’ proliferation of latently infected cells induced by
interferons or other cytokines released during the course of
immune responses that do not cause the transition from the latent
to active infection [30]; (3) latently infected cells generated during
thymopoiesis (in which immature hematopoietic precursor cells
mature after a series of replication, differentiation and selection
steps) suggested by the SCID-hu (Thy/Liv) mouse model [58]; (4)
latently infected cells transported from drug sanctuary sites or cells
latently infected by virus released from drug sanctuary sites. A
recent study by Chomont et al. [39] provides the first evidence
supporting that the latent reservoir size and persistence can be
maintained by homeostatic proliferation of latently infected cells.
The proliferation of cells with provirus was also observed in
another study [59]. Motivated by these mechanisms of reservoir
replenishment, we include a logistic term that represents
homeostatic proliferation of latently infected cells in the basic
model (see Eq. (7) in Methods).
The homeostasis model can robustly describe the multiphasic
viral decline following initiation of combination antiretroviral
treatment, and maintain both low-level persistent viremia and the
latent reservoir during therapy. Figure 9 shows the latent reservoir
size, viral load and the ratio of relative contributions to the latent
reservoir persistence of ongoing viral replication to latently infected
Figure 8. Sensitivity tests on several parameters when studying the relative contributions using model (6). The upper panels: the latent
reservoir size; the middle panels: viral load; and the lower panels: the ratio of the relative contributions, i.e., the ratio of g(1{ )kVT to
{f(t)aL0z(1{f(t))rLa. In column A, we use different activation rates: a~0:03 day{1 (blue solid), a~0:1 day{1 (red dashed), and a~0:3 day{1
(purple dotted). There is no change in the ratio of relative contributions. In column B, we use different fractions of new infections that result in
latency: g~0:001 (blue solid), g~0:005 (red dashed), and g~0:01 (purple dotted). In column C, we use different reversion rates to latency:
r~0:01 day{1 (blue solid), r~0:005 day{1 (red dashed), and r~0:001 day{1 (purple dotted). The other parameter values used are the same as
those in Figure 7.
doi:10.1371/journal.pcbi.1000533.g008
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we let the proliferation rate r change but fix the total body carrying
capacity of latently infected cells to be 8|106 cells (i.e.,
Lmax~32 cells=mL). We observe that different latently infected
cell proliferation rates yield different viral loads and different decay
rates of the latent reservoir during the third phase. A larger r leads
to higher levels of virus and latently infected cells. Consequently, a
larger r corresponds to a slower decay or a longer half-life of the
viral loadandthelatent reservoirduringthethird phase(Figures9A
and 9B). In the second row, we show the changes in latently
infected cells and viral loads with a fixed homeostatic proliferation
rate, r~0:011 day{1. The total body carrying capacity of latently
infected cells varies from 106 to 2|107 cells per patient (i.e., Lmax
varies from 4 cells=mL to 80 cells=mL). The larger carrying
capacity, the higher levels of residual virus and latently infected
cells (Figures 9D and 9E). It is interesting to observe that the time
needed for the viral load to decline from the initial value
(*106 RNA copies=mL) to below 50 copies=mL is short for a
small carrying capacity. For example, when the total body carrying
capacity is 106 cells (red dash-dotted line, Figure 9E), it takes only
about two weeks for the viral load to decline from 106 to
50 copies=mL. This is not typically observed in clinical trials. The
first phase of viral decay causing 1{2 log10 viral decline usually
takes about 2 weeks and the viral load will not decrease to below the
limit of detection until a few months after initiation of HAART
[4–6]. This shortcoming can be overcome by incorporating a
second infected cell population — long-lived infected cells [4]. In
fact, Perelson et al. [4] proposed that the loss of long-lived infected
cells, such as infected macrophages with the half-life of 1{4 weeks,
might be a major contributor to the second phase. In this section,
for simplicity we do not include the long-lived population. We
choose the total body carrying capacity to be 8|106 cells (blue
solid line, Figure 9E) so that the viral load decreases to below 50
copies/mL after about three-month treatment.
We also plot the level of latently infected cells and viral load
with different g, the fraction of new infections that result in latency
Figure 9. Numerical simulations of the homeostasis model (Eq. (7)) and sensitivity tests of several parameters. The system is at steady
state and at t~0 drug is applied. A, D, G and J: the latent reservoir size; B, E, H and K: viral load; C, F, I and L: the ratio of g(1{ )kVT to
rL(1{L=Lmax), i.e., the relative contributions to the latent reservoir persistence from ongoing viral replication and latently infected cell proliferation.
A, B and C: the carrying capacity of total latently infected cells is 8|106 cells. We use different proliferation rates: r~0:011 day{1 (blue solid),
r~0:02 day{1 (green dash-dotted), and r~0:03 day{1 (red dashed). The black solid line represents the detection limit. D, E and F: r~0:011 day{1 is
fixed. Different carrying capacities of the total latently infected cells are used: 2|107 cells (green dashed), 8|106 cells (blue solid), 106 cells (red
dash-dotted). G, H and I: we use different fractions of infections that result in latency: g~0:001 (red dashed), g~0:005 (blue solid), and g~0:01 (black
dotted). J, K and L: we use different drug efficacies: ~0:75 (red dashed), ~0:85 (blue solid), ~0:95 (black dotted). r~0:011 day{1 and the
carrying capacity 8|106 cells are fixed for the last two rows. The other parameter values used are listed in Table 1.
doi:10.1371/journal.pcbi.1000533.g009
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and 9K). As g increases from 0.001 to 0.01, we do not find changes
in the viral load or the latent reservoir size (Figures 9G and 9H).
With the drug efficacy varying from 0:75 to 0:95 (ensuring that the
viral load is suppressed to below the detection limit), we observe
that the treatment potency has almost no effect on the latent
reservoir (Figure 9J), although a higher drug efficacy always yields
a lower viral load (Figure 9K). In our simulations, low levels of
viremia persist in patients despite very effective drug treatment.
This supports the idea that viral persistence under HAART is
primarily due to the activation of latently infected cells.
We further examine the relative contributions to the latent
reservoir persistence from ongoing viral replication and latently
infected cell proliferation (i.e., the ratio of g(1{ )kVT to
rL(1{L=Lmax)) in the last column (Figures 9C,9 F,9 I and 9L).
We plot the ratio beginning at 100 days after treatment because
we are interested in the relative contributions to the latent
reservoir persistence when viral load is suppressed to below the
detection limit. The ratio is very small for a wide range of
parameter values (Figures 9C,9 F,9 I and 9L). This suggests that
latently infected cell proliferation rather than residual viral
replication is major factor contributing to the latent reservoir
persistence during effective treatment.
The model with homeostatic proliferation of latently infected
cells can also generate viral blips given intermittent bursts of
activation of latently infected cells (i.e., increasing aL randomly)
upon encounter with their specific antigens. Figure 10 delineates
the transition rate aL, the time evolution of the latent reservoir and
viral load with different proliferation rates: (A) r~0:03 day{1;( B)
r~0:02 day{1;( C) r~0:011 day{1. We use a Poisson process to
model the encounter between latently infected cells and their
relevant antigens. The average waiting time between two
encounters is assumed to be two months. In the absence of high
levels of specific antigen, the transition rate is assumed to be
the base value, aL~0:01 day{1. When the specific antigen is
present, antigenic stimulation increases the transition rate by
DaL. Some factors such as the antigen concentration and
specificity may lead to different transition rates. Here we assume
DaL~0:01:u(0,20) day{1, where 0:01 is the base value and
u(0,20) is a number chosen from a uniform distribution over the
interval ½0,20 . We further assume that the duration that each
activation lasts obeys a normal distribution N(7,2). As the
homeostatic proliferation rate r decreases from 0:03 day{1
(Figure 10A)t o0:011 day{1 (Figure 10C), the decay rate of the
latent reservoir increases. This is not surprising since with
decreasing r there is less self-renewal of latently infected cells. At
Figure 10. Simulations of the homeostasis model (Eq. (7)) with occasional increases of the transition rate aL. A Poisson process with an
average waiting time of 2 months is used to model the random encounter between latently infected cells and antigens. We assume the total body
carrying capacity of latently infected cells is 8|106 cells. Column A: r~0:03 day{1; column B: r~0:02 day{1; column C: r~0:011 day{1. Different
values of r represent different potentials of latently infected cells to renew themselves, and thus lead to different decay rates of the latent reservoir.
The other parameter values used are listed in Table 1.
doi:10.1371/journal.pcbi.1000533.g010
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cells is able to maintain the latent reservoir size at a very stable
level (Figure 10A).
The frequency of viral blips is also affected by the renewal
potential since viral blips come directly from activation of latently
infected cells. In the case of a weak renewal potential
(r~0:011 day{1, Figure 10C), a rapid decay of the latent
reservoir may not generate a viral blip (w50 RNA copies=mL)
even if there is activation occurring. Thus, with a small r,w e
expect a small number of viral blips over longer periods (similar to
the case of a small p in Table 2). This also supports the observation
that there is a strong inverse correlation between the decay of the
latent reservoir and the number of intermittent viremic episodes
observed per year [23].
Discussion
Although several months of HAART is usually able to reduce
the viral load in HIV-infected patients successfully to below the
detection limit of standard assays, 50 RNA copies/mL, a low level
of virus can still be detected in plasma by more sensitive assays
[7,8]. Despite many years of studies, there is still no single accepted
explanation for the persistence of low-level viremia. It was initially
thought that antiretroviral drugs would not be capable of
completely suppressing residual viral replication, particularly in
those sites that have poor drug penetration [60]. Changes in HIV-
1 proviral sequences in peripheral blood mononuclear cells
(PBMCs) [38], and several other lines of evidence (reviewed in
[61]) also suggest that low-level ongoing replication exists in
patients on HAART whose plasma HIV-1 RNA measurements
are below the limit of detection.
However, even if HAART is potent enough to block all new
infections of susceptible T cells, virus may still be released from a
stable reservoir composed of latently infected CD4z T cells.
Studies of children with plasma virus levels below the detection
limit showed that the existent virus lacked protease inhibitor
resistance mutations despite the frequent use of the protease
inhibitor nelfinavir, which has a low mutational barrier to
resistance [62]. Protease sequences resembled those of virions
from latently infected CD4z T cells, indicating that the low-level
virus might originate from the latent reservoir. Amplification of
plasma viral genomes in both children and adults showed that the
low-level virus does not exhibit new, HAART-selected mutations
and suggested that the viremia results primarily from archival, pre-
HAART virus that comes from activation of latently infected cells
[63]. Rebounding virus in patients after interruption of long-term
potent treatment was also shown to originate from activation of
latently infected cells [64,65]. This further supports that the low-
level persistent viremia during HAART comes from the latent
reservoir since this continuously produced virus is most likely to
rebound when treatment is stopped. Quantitative understanding
of the factors and their contributions to persistent low-level viremia
would provide valuable information that potentially could allow
the design of more effective treatment strategies.
The mechanism for the stability of the latent reservoir in the
setting of HAART remains controversial. The observation that
intensification of antiretroviral therapy can accelerate the decay of
the latent reservoir in some patients [66] suggests that residual
viral replication may replenish the latent reservoir through de novo
infection of susceptible cells on HAART [23,56]. However, to
what degree residual viral replication reseeds the latent reservoir in
the setting of current HAART is still unclear. A recent study by
Dinoso et al. [67] showed that treatment intensification could not
reduce residual HIV-1 viremia in patients on HAART. Another
explanation for the latent reservoir persistence stems from the
intrinsic slow turnover of long-lived resting memory CD4z T cells
[21,22,36,68]. Recent evidence that some patients do not develop
drug resistance despite long periods of HAART appears to support
the hypothesis that the reservoir stability comes from the intrinsic
stability of latently infected cells rather than ongoing viral
replication [69–71]. Clearly understanding the nature of the
reservoir stability is of significant importance since it is directly
related to treatment strategies. If the latent reservoir is reseeded by
low-level virus production due to the inability of antiretroviral
therapy to completely suppress viral replication, then intensifica-
tion of current regimens might help diminish the size of the
reservoir. If the reservoir stability comes from the intrinsic stability
of the latently infected cell population, then immune activation
strategies or other means of flushing the reservoir have to be
developed before virus eradication can be achieved.
Most well-suppressed patients with plasma HIV-1 RNA below
the detection limit of 50 copies/mL demonstrate transient episodes
of viremia above the limit (viral blips) [7,23]. Because of non-
intensive sampling, the characteristics of blips, such as the
occurrence timing, frequency, duration and amplitude, are not
well-known. The origin and the clinical significance of viral blips
under seemingly effective antiretroviral treatment remain unclear.
Viral blips may come from higher levels of virus production [72]
due to transient reduced drug concentrations, or increased target
cells secondary to opportunistic infection or vaccination
[27,33,73–76]. They may also result from viral release from the
latent reservoir because of heightened immune activation during
vaccination or illness [27,40,63]. Nettles et al. [26] suggested viral
blips could also be the result of laboratory error or statistical
variation. Despite plasma HIV-1 RNA greater than the detection
limit, viral blips have been reported not to be associated with
virological failure [72,77–79]. However, in some studies they have
been associated with viral evolution [80], including the selection of
drug resistant variants [81–83], an increased risk of clinical failure
[55], and a slower decay of the latent reservoir [23]. Whether
there exists the evolution of drug resistance during blips seems to
depend on the amplitude of blips—the study by Easterbrook et al.
[82] suggested that patients with transient viremia greater than
400 copies/mL are three times more likely to experience sustained
viral rebound compared with those who maintain undetectable
viral load.
In many mathematical models, the steady state viral load is very
sensitive to small changes of drug efficacy and thus they cannot
robustly describe the low viral load persistence during HAART
[28]. It is also difficult to model the stability of the latent reservoir
in the setting of potent treatment unless the latent cell death rate
and the transition rate from the latent to productive state are
extremely small [31] or balanced by bystander proliferation [30].
If viral blips also result from activation of latently infected cells, as
suggested in [27,40,63], then this activation will accelerate the
decay of latently infected cells and deplete the latent reservoir
quickly, contrary to what was observed in clinical studies. In an
attempt to examine whether intermittent viral blips can occur
without seriously depleting the latent reservoir, we developed a
new mathematical model that studies the latently infected cell
response when cells encounter their relevant antigens.
Our model can robustly maintain the stability of the latent
reservoir and meanwhile generate viral blips with reasonable
duration and amplitude in infected individuals in the setting of
HAART. We hypothesize that latently infected cells act similar to
other memory cells and experience programmed proliferation
and contraction upon antigenic stimulation by their recall
antigens. During the response, a portion of activated latently
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viral blips. In the meanwhile, a small fraction of activated cells
revert back to the resting state, providing a potential to replenish
the latent reservoir. An interesting result is that this model can
reconcile the divergent estimates of the decay rate of the latent
reservoir in the literature. The half-life of the reservoir decay is
largely determined by the frequency and duration of antigenic
stimulation and by how many times the resultant activated
latently infected cells proliferate during the latent cell response. In
addition, we observe that assuming activated T cells remain at a
low level after the rapid contraction phase (the biphasic decay
model, i.e., Eq. (6)) can maintain a low level of viremia. This
suggests that latently infected cell activation solely can maintain
low-level viremic persistence and produce intermittent viral blips
simultaneously, with the latent reservoir occasionally replenished.
Model simulations show that the levels of persistent viremia and
latently infected cells are not correlated with HAART potency,
which suggests that low viral load persistence and the stability of
the latent reservoir need not arise from ongoing active replication
during HAART.
The conclusion that ongoing viral replication is a minor factor
contributing to viral and the latent reservoir persistence is
consistent with the results of recent studies [31,32,65,84]. Using
an assay capable of detecting HIV-1 RNA down to 1 copy/mL
[8], Maldarelli et al. [84] suggested that more than 80% of patients
on HAART had quantifiable viremias (with the median of 3.1
copies/mL) for at least two years after initiation of therapy, and
that the level of persistent viremia was correlated with pretherapy
viremia, or ‘‘set point’’, but not with the specific treatment
regimen (i.e., lopinavir/ritonavir versus nelfinavir as the protease
inhibitor in HAART). These observations suggest that the
persistent low-level viremia is derived from virus production by
reservoirs infected prior to initiation of therapy, rather than
ongoing viral replication during HAART. Bailey et al. [85]
reported that in some patients a single, homogenous but distinct
viral sequence (PPC) dominated the residual plasma virus but
could not be readily found in the patient’s resting CD4z cells in
peripheral blood. With the assumption that reservoir replenish-
ment by ongoing viral replication in the presence of the PPC
would eventually lead to incorporation of the PPC into the latent
reservoir, and using a simple mathematical model to constrain the
maximum rate of reservoir replenishment by viral replication [32],
they suggest that ongoing viral replication during HAART is
unlikely to be a major factor contributing to the stability of the
latent reservoir. By characterizing rebounding virus during the
structured treatment interruptions, Joos et al. [65] argue against
persistence of ongoing low-level viral replication in patients under
suppressive combination therapy.
Motivated by the observation that latently infected cells have
the potential to renew themselves when stimulated by their
previously encountered antigens, a much simpler phenomenolog-
ical model with homeostatic proliferation of latently infected cells
was proposed to study viral persistence and HIV-1 blips. The idea
that the stability of the latent reservoir can be maintained by
homeostatic proliferation of latently infected cells is also supported
by a very recent experimental study [39]. Our model is able to
simulate the multiphasic viral decay in patients after initiation of
HAART. In this model, the homeostatic proliferation rate of
latently infected cells is a key factor determining the half-life of the
latent reservoir decay. A few factors, such as the concentration of
antigen and its specificity, may affect the proliferation capacity of
latently infected cells. In addition, the decay of the latent reservoir
is inversely correlated with the frequency or amplitude of viral
blips, as has been observed in the clinical study [23].
Considering that the latent reservoir consists of heterogeneous
mixture of latently infected T-cell clones that respond differently to
different antigens, our models can be generalized to account for
the heterogeneity of latently infected cells. For example, we can
extend the homeostasis model by including multiple subpopula-
tions of latently infected cells, with each subpopulation having a
different transition rate aL (see Eq. (7)). We expect that those
subpopulations specific for frequently encountered antigens will be
preferentially activated and removed from the reservoir, whereas
those subpopulations that are specific for rarely encountered
antigens may persist without activation or be activated slowly and
dominate the latent reservoir. However, this prediction can be
affected by the proliferation ability (r) of each subpopulation.
When we extend the model with programmed expansion and
contraction by including multiple subpopulations of latently
infected cells, the situation is a little different. Without assuming
homeostatic proliferation of latently infected cells, depletion of one
subpopulation does not imply other subpopulations will grow. The
dynamics of each latently infected subpopulation depends on the
proliferation ability of that subpopulation (i.e., the parameter p in
Eq. (4)) and the reversion rate (r) from the activated to latent state.
Unfortunately, currently we do not have data on the heterogeneity
of the latent reservoir that can be compared with these models.
Given that the latent reservoir has been identified as a major
barrier to virus eradication with current combination therapy [86],
elimination of this reservoir by novel therapeutic approaches is
required before eradication can be achieved [87]. Our modeling
results suggest that the stability of the latent reservoir is most likely
due to the intrinsic stability of resting memory CD4z T cells and
their occasional replenishment by antigenic stimulation. Thus,
simply intensifying current therapy to further suppress ongoing
active replication may not have much impact on the decay of the
latent reservoir. Immune stimulation with activating agents has
been proposed as a means to ‘‘flush’’ virus out of the latent
reservoir. However, efforts to purge the latent reservoir with these
agents have unfortunately shown only limited success. For
example, although a combination of OKT3 and recombinant
human IL-2 resulted in apparent T cell activation and prolifer-
ation [88], patients failed to achieve measurable purging of the
cellular HIV reservoir. Moreover, side-effects were serious and
antibodies against OKT3 developed rapidly in all patients. More
importantly, if the activation of T cells in the latent reservoir also
induces renewal of the latent pool as suggested by the models
developed in this study, then activating agents could do more
harm than good. Partial eradication of the latent reservoir will not
be of significant benefit to infected individuals since theoretically a
single infected cell has the potential to rekindle infection [89].
Therefore, a combination of activating agents with antiretroviral
drugs can be useful only if they lead to a complete elimination of
all the latent reservoirs.
Unfortunately, as viral levels are driven down, say below 1 RNA
copy/mL, and latently infected cells become rare, it becomes
impossible to follow the dynamics of these populations. Therefore,
we must rely on mathematical models to make inferences about the
end game in viral eradication. Here we have presented a set of
models that agree with much of our knowledge about low-level
viral persistence, the latent reservoir, and viral blips. Direct
experimental tests of these models would involve the examination
of the latently infected cell response when cells are activated by
specific antigens. In addition, all of our models suggest that there is
an inverse relationship between the decay of the latent reservoir
and the frequency (or amplitude) of viral blips. Thus,more accurate
and frequent data on the latent reservoir size, the number of viral
blips and their amplitudes also can be used to test our models.
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